AI brief of an SEC Form 8-K · HeartSciences Inc. (HSCS)

HeartSciences receives FDA 510(k) clearance for MyoVista wavECG device

Neutral Impact 3 of 5 legal/regulatory Written later

On October 6, 2026, HeartSciences said the FDA granted 510(k) clearance (K260005) for its MyoVista wavECG device as a 12-lead resting electrocardiograph, but the clearance does not include the AI-ECG algorithm. The company does not intend to commercialize the device without a cleared algorithm and has no timeline for doing so, and it will evaluate options for the device and related intellectual property. The proposed business combination with Fortitude Mining Holdings continues, with closing expected in Q4 calendar 2026, subject to shareholder approval.

Key points

  • FDA granted 510(k) clearance K260005 for the MyoVista wavECG device as a 12-lead resting electrocardiograph, covering adult and pediatric patients in hospitals and healthcare facilities.
  • The clearance does not include the AI-ECG algorithm, and the company has no commercialization timeline for the device.
  • The Proposed Transaction with Fortitude, under a merger agreement dated June 23, 2026, is expected to close in Q4 calendar 2026, subject to shareholder approval.

The filing

CompanyHeartSciences Inc. (HSCS)
Form8-K, current report
Filed with the SECOct 6, 2026, 4:30 PM ET
Accession number0001213900-26-107238

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.